Filing Details

Accession Number:
0001209191-20-052700
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-01 17:40:42
Reporting Period:
2020-09-30
Accepted Time:
2020-10-01 17:40:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1000694 Novavax Inc NVAX Biological Products, (No Disgnostic Substances) (2836) 222816046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1468534 John Trizzino C/O Novavax, Inc.
21 Firstfield Road
Gaithersburg MD 20878
Evp, Cbo And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-09-30 79 $107.60 7,258 No 4 S Direct
Common Stock Disposition 2020-09-30 945 $108.57 6,313 No 4 S Direct
Common Stock Disposition 2020-09-30 353 $109.59 5,960 No 4 S Direct
Common Stock Disposition 2020-09-30 332 $110.85 5,628 No 4 S Direct
Common Stock Disposition 2020-09-30 160 $112.03 5,468 No 4 S Direct
Common Stock Disposition 2020-09-30 58 $112.78 5,410 No 4 S Direct
Common Stock Disposition 2020-09-30 214 $114.03 5,196 No 4 S Direct
Common Stock Disposition 2020-09-30 109 $115.08 5,087 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.82, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  3. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.08 to $109.07, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  4. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.17 to $110.16, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  5. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.47 to $111.27, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  6. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.60 to $112.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  7. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.83 to $114.47, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  8. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.98 to $115.20, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.